China NMPA Drug Inspection - Lanzhou Xukang Pharmaceutical Co., Ltd. - Platycodon grandiflorus

The Ningxia Food and Drug Administration, operating under the "Drug Administration Law of the People's Republic of China" and the "Regulations on the Administration of Drug Quality Sampling Inspection," released an announcement (No. 09, 2018) on August 17, 2018. This announcement communicated the findings of recent drug sampling inspections performed in the region throughout 2018. The comprehensive inspection program included 96 batches spanning 19 distinct drug varieties, encompassing chemical pharmaceuticals, traditional Chinese medicine preparations, and traditional Chinese medicine decoction pieces. Products from various manufacturers, such as Pingliang Zhukang Traditional Chinese Medicine Pieces Co., Ltd., Guangdong Hongying Technology Co., Ltd., and Ningxia Kangya Pharmaceutical Co., Ltd., were subjected to rigorous evaluation. Compliance was assessed against established standards, including the "Chinese Pharmacopoeia 2015 Edition" and other relevant national drug standards. Significantly, all 96 sampled batches were determined to be fully compliant with the stipulated quality regulations. Consequently, no violations or corrective actions were identified as necessary for any of the tested products or their respective manufacturers, indicating strong adherence to quality benchmarks within the Ningxia drug market during that period.